CAMBRIDGE, Mass., Dec. 28, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the
field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at
the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019 at 9:30 a.m. PT (12:30 p.m. ET).
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's
website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the
presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through
scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both
therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in
clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Agios Pharmaceuticals:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
Holly.Manning@agios.com
